CAJ | 학술논문

目的探讨阿立哌唑治疗利培酮所致女性患者高催乳素血症的疗效及安全性.方法 117例利培酮所致高催乳素血症的女性患者,随机分为治疗组(60例)和对照组(57例).维持原有利培酮治疗不变,治疗组加用阿立哌唑5 mg,对照组加用安慰剂治疗,疗程均为6周.于治疗第0,6周末检测催乳素,评定简明精神病量表(BPRS)、治疗中需处理的不良反应症状量表(TESS).结果 (1)治疗第6周末,治疗组催乳素[(26±6)μg/L]较基线[(112±40)μg/L]下降,差异有统计学意义(P=0.000);对照组催乳素[(99±44)μg/L]与基线[(104±34)μg/L]比较,差异无统计学意义(P=0.180).(2)治疗第6周末,治疗组催乳素下降率[(75±8)%]、正常率(82%),均高于对照组[分别为(5+30)%,4%];P均=0.000.(3)治疗第6周末,治疗组[(20.4±2.1)分]、对照组[(20.8±1.9)分]BPRS评分均较基线[分别为(21.1±1.8)分,(21.4±1.9)分]下降,P均=0.045;两组不良反应发生率相近(P=0.553).结论阿立哌唑治疗利培酮所致精神分裂症女性患者的血高催乳症有效、安全.
목적 탐토아립고서치료리배동소치녀성환자고최유소혈증적료효급안전성.방법 117례리배동소치고최유소혈증적녀성환자,수궤분위치료조(60례)화대조조(57례).유지원유리배동치료불변,치료조가용아립고서5 mg,대조조가용안위제치료,료정균위6주.우치료제0,6주말검측최유소,평정간명정신병량표(BPRS)、치료중수처리적불량반응증상량표(TESS).결과 (1)치료제6주말,치료조최유소[(26±6)μg/L]교기선[(112±40)μg/L]하강,차이유통계학의의(P=0.000);대조조최유소[(99±44)μg/L]여기선[(104±34)μg/L]비교,차이무통계학의의(P=0.180).(2)치료제6주말,치료조최유소하강솔[(75±8)%]、정상솔(82%),균고우대조조[분별위(5+30)%,4%];P균=0.000.(3)치료제6주말,치료조[(20.4±2.1)분]、대조조[(20.8±1.9)분]BPRS평분균교기선[분별위(21.1±1.8)분,(21.4±1.9)분]하강,P균=0.045;량조불량반응발생솔상근(P=0.553).결론 아립고서치료리배동소치정신분렬증녀성환자적혈고최유증유효、안전.
Objective To explore the efficacy and safety of aripiprasole in treatment of female schizophrenics with risperidone induced hyperprolactinemia. Methods All 117 female schizophrenics with hyperprolactinemia after fixed dose risperidone treatment were randomly assigned to aripiprazole group (n=60) and control group (n=57), and received additional aripiprazole 5 nag daily or placebo for 6 weeks respectively. The plasma prolactin (PBL) level was measured at weeks 0 and 6, and the Brief Psychiatric Bating Scale (BPBS) and Treatment Emergent Symptom Scale (TESS) were assessed. Results (1)Plasma prolactin levels were significantly reduced after the study compared with the baseline [(26±6) μg/L vs. (112±40)μg/L] in aripiprazole group (P= 0.000), however there were no significant difference between pre- and post treatment in control group (P =0.180). (2) At weeks 6, the decline rate and the normal ratio of plasma prolactin levels were significantly higher in aripiprazole group [(75±8) % vs. 82%]than in control group [(5±30) % vs. 4%] respectively (beth P = 0.000 ). (3) Compared with the baseline, the BPRS score showed significant reduction in both groups at the end of the study (both P=0.045). The incidence of side effects showed no significant difference between aripiprazole and control group(P =0.553). Conclusion The results indicate that aripiprazole may be effective and safe for the treatment of female schizophrenics with risperidone induced hyperprolactinemis.